ROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "ROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER"

Transcription

1 AFA From Bench to Bedside From KK DT1 10/27/ :04 PM 01 ROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER Hak Choy, MD University of Texas Southwestern Medical Center Dallas, Texas, USA

2 Orchestrating the instruments of lung cancer treatment Early Stage NSCLC: SBRT 02 Sexy and Top Advances with Radiation Therapy for Lung caner LAStage NSCLC: IGRT Advanced Stage NSCLC: SBRT

3 The Second Movement: Role of Radiation Therapy Inoperable early stage NSCLC 2. Operable early stage NSCLC 3. Stage IV NSCLC 4. Potential role of RT in combining with anti-tumour immunotherapeutics

4 The Second Movement: Role of Radiation Therapy Inoperable early stage NSCLC 2. Operable early stage NSCLC 3. Stage IV NSCLC 4. Potential role of RT in combining with anti-tumour immunotherapeutics

5 Stereotactic Body Radiation Therapy Stereotactic Body Radiation Therapy 05 Esophagus Bronchus Pulmonary vein Lung Chest wall Cord Skin RTOG 0236: 2000 cgy X 3

6 Local Control (%) RTOG 0236: Local Control / / / / / / / / / / / / / / / / / / / / / / / month local control = 98% (CI: 84%-100%) PFS in overall population 1 failure within PTV, 0 within 1 cm of PTV 0 Fail: 1 Total: Months After Start of SBRT Patients at Risk Timmerman. ASTRO 2009.

7 Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer 07 RTOG 0236: Primary (In-field + Marginal) Tumour Recurrence 60-month Primary tumour recurrence = 7% PFS in overall population Timmerman R et al. JAMA. 2010;303:

8 08 Cost-Effectiveness of Stereotactic Body Radiation Therapy vs Surgical Resection for Stage I Non-Small Cell Lung Cancer Anand Shah, MD, MPH, et al. J Thorac Cardiovasc Surg. 2012;143:

9 09 Total SBRT $14,821

10 010 Surgeon s fee $1,690-$985 Anaesthesiologist $482

11 011 Surgeon s fee $1,690-$985 Anaesthesiologist $482 + Hospital fee $46,210- $16,206

12 012 Total SBRT $14,821 Surgeon s fee $985-$1,690 Anaesthesiologist $482 Hospital fee: $16,206-$46,210 Total Surgery: $18,378-$47,677

13 Cost-Effectiveness of Stereotactic Radiation, Sublobar Resection, and Lobectomy for Early Non-Small Cell Lung Cancers in Older Adults 013 A. Comparison of sublobar resection to SABR B. Comparison of lobectomy to SABR Lobectomy PFS in overall population PFS in overall population Smith et al. J Geriatr Oncol. 2015;6:

14 The Second Movement: Role of Radiation Therapy Inoperable early stage NSCLC 2. Operable early stage NSCLC 3. Stage IV NSCLC 4. Potential role of RT in combining with anti-tumour immunotherapeutics

15 Stereotactic Ablative Radiotherapy vs Lobectomy for Operable Stage I NSCLC: A Pooled Analysis of Two Randomised Trials 015 Joe Y Chang, et al. Lancet Oncol. 2015;16:

16 ACOSOG Z4099 / RTOG PIs: Hiran C. Fernando, MD (ACOSOG); Robert Timmerman, MD (RTOG) N=420 Traditional phase III randomised trial Patients randomised to either surgery or SABR after consent Primary endpoint = 3-year overall survival

17 Pre-randomisation 017 The NSABP B-06: mastectomy to lumpectomy/xrt had very poor accrual when originally opened for enrollment NSABP re-designed the trial to utilise a randomisation that occurred prior to asking the patient to participate The re-design led to successful accrual that allowed the trial to answer the question

18 STABLEMATES Trial Schema Defined High-Risk Stage I NSCLC Screen Eligible Patients / Pre- Randomise N = 304 Consent to Accept Randomisation Assignment A c c e p t N = 254 R e j e c t N = 50* *Anticipated (actual assignment rate will be monitored) Arm 1: Sublobar Resection N = 127 Arm 2: SAbR N = 127 Consent to Be Observed After Standard of Care Therapy A c c e p t N = 45 R e j e c t N = 5* Follow for Overall Survival, Toxicity, and Patterns of Failure 018 Follow for Overall Survival Failure to Consent (Off Study)

19 The Second Movement: Role of Radiation Therapy Inoperable early stage NSCLC 2. Operable early stage NSCLC 3. Stage IV NSCLC 4. Potential role of RT in combining with anti-tumour immunotherapeutics

20 Is There a Role for Consolidative Stereotactic Body Radiation Therapy Following First-line Systemic Therapy for Metastatic Lung Cancer? A Patterns-of-Failure Analysis 020 Careful assessment of pattern of failure (POF) Local (L, existing sites) or distant (D, new sites) Brain mets scored separately 64 patients with stage IIIB-IV NSCLC Median time to progression = 3.9 months 91% L only failure in 64%, L+D in 27%, D only in 9% 1st-line therapy fails to control gross disease in 91%

21 Treatment in Stage IV NSCLC 021 How do you treat stage IV NSCLC patients after 1st-line systemic therapy? Current paradigm: Maintenance chemotherapy Continue targeted therapy until development of T790M or L1196M Observation with initiation of 2nd-line therapy at time of progression Some 30%-50% of patients who progress thru 1st-line chemo/targeted therapy do not receive further therapy PS being one reason (related to toxicity) Proposed paradigm: Locally ablative treatment with hypofractionated radiotherapy + maintenance chemotherapy after 4-6 cycles/month of chemo/targeted therapy

22 A Phase II Trial of 2 nd -line Erlotinib (Tarceva ) in Combination With Stereotactic Body Radiation Therapy (SBRT) for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) 022 UTSW/U Denver Trial NSCLC 1. Progressed after prior systemic therapy 2. 6 discrete lesions 3. Eligible for erlotinib and SBRT to all lesions 4. unscreened Week 1 Begin erlotinib 150 mg/d Weeks 2-4 Continue erlotinib Begin SBRT to all involved sites of disease* Post-SBRT Erlotinib until disease progression or unacceptable toxicity Systemic SBRT! *VERY CONSERVATIVE SBRT DOSES, eg, 1 19 Gy, 3 11 Gy, 5 8 Gy.

23 023 J Clin Oncol Oct patients with stage IV NSCLC who had progressed through platinum-based chemotherapy Erlotinib and concurrent SBRT to all sites (up to 6) Pattern of Failure Number (%) out of 23 patients Sites of Failure by Patient: Within SBRT treated area 1 (4) Outside SBRT field 6 (26) None 17 (74) Distant Failure Sites Liver 4 (17) Brain 2 (9) Pancreas 1 (4) Lymph node 1 (4)

24 024 J Clin Oncol Oct patients with stage IV NSCLC who had progressed through platinum-based chemotherapy Erlotinib and concurrent SBRT to all sites (up to 6) Dramatically improved median PFS and OS compared to historical controls

25 025 J Clin Oncol Oct 27 JCO. December 1, 2014 vol. 32 no. 34: Best of JCO 2015 Thoracic Oncology Edition is a collection of the most-accessed clinical research articles recently published in the Journal of Clinical Oncology (JCO) focusing on thoracic oncology. Access Best of JCO 2015 Thoracic Oncology Edition August 2015.

26 Randomised Phase II Trial Comparing Maintenance Chemotherapy vs SBRT Followed by Maintenance Chemotherapy for Stage IV NSCLC Patients With Limited Metastatic Disease 026 Stage IV NSCLC Patients Any 1 st Line Chemotherapy CR Progression Partial Response Stable Disease Maintenance Chemotherapy SBRT to all sites of disease determined by CT or PET/CT Chemo 6 Locations of Disease = Randomisation Patient Off Study When progression by imaging cannot be adequately addressed by SBRT (either from too many sites of disease progression or failures within previously treated sites with SBRT) Primary End Point PFS Secondary End Points OS, toxicity, biologic correlates, cost-benefit analysis, QoL Longitudinal Biologic Correlates Could include CTCs, cytokines, growth factors, biopsy of recurrences and evaluation of SNPs, deep sequencing, etc

27 027 Why SBRT worked so well even in metastatic lung cancer patients?

28 The Second Movement: Role of Radiation Therapy Inoperable early stage NSCLC 2. Operable early stage NSCLC 3. Stage IV NSCLC 4. Potential role of RT in combining with anti-tumour immunotherapeutics

29 The Second Movement: Role of Radiation Therapy 029 Detectable/Treatable tumor. RT (or SBRT) Undetectable/Untreatable micro metastasis Abscopal effects

30 RT Can Augment Immune Response 030 Abscopal Effects Shiao and Coussens. J Mammary Gland Biol Neoplasia

31 Abscopal Effects of Radiation Therapy 031 Postow et al. N Engl J Med. 2012;366:

32 Abscopal Effects of Radiotherapy After Immunotherapy 032 A 54-y-old male patient received 4 cycles of ipilimumab 3 mg/kg (June to August 2012) followed by palliative whole-brain radiotherapy (WBRT) Grimaldi et al. Oncoimmunology. 2014;3:e28780.

33 Figure 1. Patient survival according to abscopal responses. Kaplan-Meier curves depicting overall survival (OS) curves among patients who received RT after progression with ipilimumab, according to the presence or absence of an abscopal response (present in 11 patients and absent in 10 patients). Groups were compared using the log-rank test; P=

34 Immune Suppression at Multiple Points in the Cancer-Immunity Cycle 034

35 Reversing Immune Suppression at Multiple Points in the Cancer-Immunity Cycle 035 Anti-CTLA4 RT RT RT Anti-PD-1 Anti-PD-L1

36 SBRT: 20 Gy x

37 SBRT: 20 Gy x

38 RADVAX Trial Schema (Stage IV Melanoma) Hypofractionated RT to single index lesion (over 3-7 days) 038 Enrollment Baseline studies and staging RT #1 RT #2 RT #3 ipilimumab iv q3weeks x 4 1 st ipi 5 days after RT Follow up Restaging Stratum 1: lung or bone DL1 8 Gy x 2; DL2 8 Gy x 3 Stratum 2: liver or s.c. DL1 6Gy x 2; DL2 6 Gy x 3 UPCC RADVAX Clinicaltrials.gov NCT Twyman-Saint et al. Nature. April Biosamples and analysis 22 patients enrolled: Lung (n=10); liver (n=3); subcutaneous (n=9) Enrolling stratum 1 at Dose Level 2

39 Tumour Response to SBRT/Ipilimumab 039 Baseline 4d s/p SBRT 2mo s/p ipi #4 SBRT to index lesion Twyman-Saint et al. Nature. April 2015.

40 Tumour response at unirradiated sites (% change from baseline) Clinical Response to SBRT/Ipilimumab 040 Twyman-Saint et al. Nature. April 2015.

41 What is best RT dose and treatment schedule? 2. Does the target matter tumour, stromal, endothelium 3. Encouraging responses, but why is unresponsiveness still common? 4. What are the biomarkers for response? 5. Can additional immune checkpoint blockade be used or combined to improve outcome? Twyman-Saint et al. Nature. April 2015.

42 Proportion Survival RT + Combined CTLA4 and PD-L1/PD-1 Blockade Improves Survival and Provides Long-Term Immunity 042 Anti CTLA4 PD-1 PDL-1 Days Twyman-Saint et al. Nature. April 2015.

43 Conclusions 1. Sub-optimal, protracted fractionation schedules were appropriate in previous decades due to technology limitations 2. SBRT has already been established as standard care for early stage inoperable NSCLC 3. SBRT will likely become mainstream for eradicating/ debulking gross tumours OF ANY CANCER STAGE 4. RT clearly influences multiple points of the Cancer-Immunity Cycle 5. RT with anti-tumour immunotherapeutics can potentially yield effective and durable suppression of tumours, resulting in improved outcomes for lung cancer patients

44 CONVERSATIONS IN ONCOLOGY ORCHESTRATING THE INSTRUMENTS OF LUNG CANCER TREATMENT

Moving forward, where are we with Clinical Trials?

Moving forward, where are we with Clinical Trials? Moving forward, where are we with Clinical Trials? Dennis A. Wigle Division of Thoracic Surgery Mayo Clinic AATS/STS General Thoracic Surgery Symposium Sunday, April 27 th 2014 2012 MFMER slide-1 Where

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

More information

SAKK Lung Cancer Group. Current activities and future projects

SAKK Lung Cancer Group. Current activities and future projects SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation

More information

Radioterapia panencefalica. Umberto Ricardi

Radioterapia panencefalica. Umberto Ricardi Radioterapia panencefalica Umberto Ricardi Background Systemic disease to the brain is unfortunately a quite common event Radiotherapy, especially with the great technical development during the past decades,

More information

Probe: Could you tell me about when?

Probe: Could you tell me about when? PERIODIC ASSESSMENT OF TREATMENT AND VITAL/DISEASE STATUS Periodic Assessment of Cancer Treatment and Disease Status (To be administered to patient at 3 months and reviewed at 6, 9 and 12 months) Instructions:

More information

Updates in Breast Cancer: Radiation. Shirnett Matthews, MD Radiation Oncology Cancer Centers of the Carolinas

Updates in Breast Cancer: Radiation. Shirnett Matthews, MD Radiation Oncology Cancer Centers of the Carolinas Updates in Breast Cancer: Radiation Shirnett Matthews, MD Radiation Oncology Cancer Centers of the Carolinas Hughes et al. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 years of Age

More information

Lung Cancer Treatment Guidelines

Lung Cancer Treatment Guidelines Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,

More information

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from

More information

Radiotherapy in locally advanced & metastatic NSC lung cancer

Radiotherapy in locally advanced & metastatic NSC lung cancer Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced

More information

CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015. 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV

CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015. 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV Meta-analisis LACE: adyuvancia vs no adyuvancia Pignon JP, et al.

More information

Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology

Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.

More information

Whole Breast Radiation Is The Standard of Care For Breast Cancer Treatment. Kathryn Sullivan, R2 November 27, 2006

Whole Breast Radiation Is The Standard of Care For Breast Cancer Treatment. Kathryn Sullivan, R2 November 27, 2006 Whole Breast Radiation Is The Standard of Care For Breast Cancer Treatment Kathryn Sullivan, R2 November 27, 2006 History of Breast Cancer Treatment Radical Mastectomy: Prior to 1894 treatment was wide

More information

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate + Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN

More information

Thank you to our webinar sponsors:

Thank you to our webinar sponsors: Treatment Approaches for Pancreatic Cancer January 27, 2016 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation

More information

Trials in Elderly Melanoma Patients (with a focus on immunotherapy)

Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP

More information

What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center

What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.

More information

Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation

Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable

More information

Current Status and Perspectives of Radiation Therapy for Breast Cancer

Current Status and Perspectives of Radiation Therapy for Breast Cancer Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic

More information

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the

More information

Uncertainty with Imageguided Radiotherapy in Lung Cancer

Uncertainty with Imageguided Radiotherapy in Lung Cancer Uncertainty with Imageguided Radiotherapy in Lung Cancer Joe Y. Chang, MD, PhD Clinical Section Chief Thoracic Radiation Oncology Director Stereotactic Ablative Radiotherapy Program Lung Cancer No. 1 cancer

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

Alternatives to Surgical Resection for Early Stage Lung Cancer

Alternatives to Surgical Resection for Early Stage Lung Cancer Alternatives to Surgical Resection for Early Stage Lung Cancer Neil A. Christie MD University of Pittsburgh Medical Center Department of Thoracic Surgery Allied Health Personnel Symposium AATS 2014 Conflicts

More information

Comparing Immunotherapy with High Dose IL-2 and Ipilimumab

Comparing Immunotherapy with High Dose IL-2 and Ipilimumab Comparing Immunotherapy with High Dose IL-2 and Ipilimumab Michael K Wong MD PhD FRCPC mike.wong@med.usc.edu Disclosures Speaker s Bureau, Advisory Boards, Consultant: Prometheus Bristol Myers Squibb Novartis

More information

Radiation Therapy in the Treatment of

Radiation Therapy in the Treatment of Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:

More information

PET/CT Imaging in Lung Cancer

PET/CT Imaging in Lung Cancer PET/CT Imaging in Lung Cancer Mylene T. Truong, MD Mylene T. Truong M.D. Objectives To discuss the role of PET/CT in the staging of lung cancer To review the recommendations from American Society of Clinical

More information

PET/CT in Lung Cancer

PET/CT in Lung Cancer PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT

More information

Implementation Date: April 2015 Clinical Operations

Implementation Date: April 2015 Clinical Operations National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:

More information

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3

More information

Post-PET Restaging Cancer Form National Oncologic PET Registry

Post-PET Restaging Cancer Form National Oncologic PET Registry Post-PET Restaging Cancer Form National Oncologic PET Registry Facility ID #: Registry Case Number: Patient Name: Your patient had a PET scan on: mm/dd/yyyy. The PET scan was done for restaging of (cancer

More information

Based on SIOG recommendations: Lancet Oncol 2007 (8) p 1101

Based on SIOG recommendations: Lancet Oncol 2007 (8) p 1101 Breast cancer in the older pts H. Wildiers University Hospitals Leuven Belgium Based on SIOG recommendations: Lancet Oncol 2007 (8) p 1101 Introduction INCIDENCE: >40% occurs > 65y of age TUMOR BIOLOGY:

More information

Recruiting now. Could you help by joining this study?

Recruiting now. Could you help by joining this study? Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate

More information

Particle Therapy for Lung Cancer. Bradford Hoppe MD, MPH Assistant Professor University of Florida bhoppe@floridaproton.org

Particle Therapy for Lung Cancer. Bradford Hoppe MD, MPH Assistant Professor University of Florida bhoppe@floridaproton.org Particle Therapy for Lung Cancer Bradford Hoppe MD, MPH Assistant Professor University of Florida bhoppe@floridaproton.org Content Rationale for Particle Therapy in Lung Cancer Proof of Principle Treatment

More information

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:

More information

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the

More information

National Clinical Trials Network Groups Update Fall 2014

National Clinical Trials Network Groups Update Fall 2014 National Clinical Trials Network Groups Update Fall 2014 Walter J Curran, Jr, MD An NRG Oncology Group Chair Executive Director Winship Cancer Institute of Emory University Atlanta, GA NCTN Groups Update

More information

Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer. Shannon Acker April 4, 2011

Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer. Shannon Acker April 4, 2011 Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer Shannon Acker April 4, 2011 Rectal Cancer 40,870 new cases in the US in 2009 49,920 deaths from colorectal cancer Second leading cause

More information

The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer

The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer BIT's 4th World Cancer Congress 2011 People s Republic of China Dalian The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in treated with DBM therapy Retrospective observational

More information

Definitive Treatment of Poor-Risk Patients with Stage I Lung Cancer. A Single Institution Experience

Definitive Treatment of Poor-Risk Patients with Stage I Lung Cancer. A Single Institution Experience ORIGINAL ARTICLE Definitive Treatment of Poor-Risk Patients with Stage I Lung Cancer A Single Institution Experience Michael Hsie, MD,* Stefania Morbidini-Gaffney, MD,* Leslie J. Kohman, MD, Elisabeth

More information

Management of low grade glioma s: update on recent trials

Management of low grade glioma s: update on recent trials Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,

More information

PALLIATIVE RADIATION EVIDENCE BASED APPROACH. Liliana Bustamante July 10 th, 2013

PALLIATIVE RADIATION EVIDENCE BASED APPROACH. Liliana Bustamante July 10 th, 2013 PALLIATIVE RADIATION EVIDENCE BASED APPROACH Liliana Bustamante July 10 th, 2013 Why this topic? A recent article by Dr. Aileen Chen of the Dana-Farber Cancer Institute in Boston showed that in patients

More information

NEOADJUVANT CHEMOTHERAPY BREAST CANCER RADIATION ONCOLOGY ISSUES To Whom and How?

NEOADJUVANT CHEMOTHERAPY BREAST CANCER RADIATION ONCOLOGY ISSUES To Whom and How? NEOADJUVANT CHEMOTHERAPY BREAST CANCER RADIATION ONCOLOGY ISSUES To Whom and How? Bruce G. Haffty, MD Professor and Chair Department of Radiation Oncology Rutgers, The State University of New Jersey Cancer

More information

Should patients with resectable pancreatic cancer receive pre op chemotherapy? YES. Bassel El Rayes

Should patients with resectable pancreatic cancer receive pre op chemotherapy? YES. Bassel El Rayes Should patients with resectable pancreatic cancer receive pre op chemotherapy? YES Bassel El Rayes The Facts 1. Resection Outcomes Are Poor NCDB SEER Survival for early stage resectable pancreas cancer

More information

Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014

Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014 Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology November 17, 2014 Forward-looking statements Our discussions during this conference call will

More information

London Cancer Guidelines for the management of Carcinomas of the Pancreas

London Cancer Guidelines for the management of Carcinomas of the Pancreas London Cancer Guidelines for the management of Carcinomas of the Pancreas June 2014 Contents Staging (AJCC 7th Edition)... 2 Primary Tumor:... 2 Regional Lymph Nodes:... 2 Distant Metastases:... 2 Stage

More information

FRCPC The Addie MacNaughton Chair in Thoracic Radiation Oncology

FRCPC The Addie MacNaughton Chair in Thoracic Radiation Oncology Lung Cancer : Improving the Cure Rate with Radiation Andrea Bezjak, MDCM, MSc, FRCPC The Addie MacNaughton Chair in Thoracic Radiation Oncology Outline of Presentation Management of Lung Cancer Changes

More information

Stage IIIB disease includes patients with T4 tumors,

Stage IIIB disease includes patients with T4 tumors, Guidelines on Treatment of Stage IIIB Non-small Cell Lung Cancer* James R. Jett, MD, FCCP; Walter J. Scott, MD, FCCP; M. Patricia Rivera MD, FCCP; and William T. Sause, MD, FACR Stage IIIB includes patients

More information

Combining radiation therapy with immunotherapy: clinical translation. Silvia C Formenti, M.D.

Combining radiation therapy with immunotherapy: clinical translation. Silvia C Formenti, M.D. Combining radiation therapy with immunotherapy: clinical translation Silvia C Formenti, M.D. Disclosures Consultant/Speaker: Bristol Myers Squibb, Varian, Jensen, Elekta, Regeneron Principal Investigator:

More information

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Background The Cancer Institute New South Wales Oncology Group Lung (NSWOG Lung) identified the need for the development

More information

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized

More information

Principal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Principal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,

More information

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. Presenter: Jonathan E. Schwartz, MD

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. Presenter: Jonathan E. Schwartz, MD Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening Disclosures: I, like many physicians, receive compensation from the government and their insurance company cronies who completely

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Endpoint Selection in Phase II Oncology trials

Endpoint Selection in Phase II Oncology trials Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill aivanova@bios.unc.edu Primary endpoints in Phase II trials Recently looked at journal articles

More information

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone

More information

Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,

More information

The Need for Accurate Lung Cancer Staging

The Need for Accurate Lung Cancer Staging The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide

More information

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional

More information

The Role Of Cytoreductive Surgery In The Era Of Targeted Therapy For Metastatic Renal Cell Carcinoma. Cytoreductive Surgery

The Role Of Cytoreductive Surgery In The Era Of Targeted Therapy For Metastatic Renal Cell Carcinoma. Cytoreductive Surgery The Role Of Cytoreductive Surgery In The Era Of Targeted Therapy For Metastatic Renal Cell Carcinoma Robert A. Figlin MD., FACP Acting Director City of Hope Comprehensive Cancer Center Cytoreductive Surgery

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

Local Breast Irradiation Controversies Following Neoadjuvant Chemotherapy: Can Radiotherapy Be Downstaged As Well?

Local Breast Irradiation Controversies Following Neoadjuvant Chemotherapy: Can Radiotherapy Be Downstaged As Well? Local Breast Irradiation Controversies Following Neoadjuvant Chemotherapy: Can Radiotherapy Be Downstaged As Well? Nancy Wiggers, MD Northside Radiation Oncology Consultants Atlanta, Georgia Approximately

More information

A new score predicting the survival of patients with spinal cord compression from myeloma

A new score predicting the survival of patients with spinal cord compression from myeloma A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven

More information

SBRT (Elekta), 45 Gy in fractions of 3 Gy 3x/week for 5 weeks (N=22) vs.

SBRT (Elekta), 45 Gy in fractions of 3 Gy 3x/week for 5 weeks (N=22) vs. Uitgangsvraag 6: Wat is de plaats van stereotactische radiotherapiebehandeling (SBRT) bij HCC patiënten? Primaire studies I Study ID II Method III Patient characteristics IV Intervention(s) V Results primary

More information

Multidisciplinary discussion of: Early staged NSCLC

Multidisciplinary discussion of: Early staged NSCLC Multidisciplinary discussion of: Early staged NSCLC 2 different classes of patients Stage IIIA pt2pn2 Stage IIB pt3pn0 2 different classes of patients 50% 40% 30% 20% 10% 3y survival 50% 40% 30% 20% 10%

More information

PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients

PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients PO: Pathologic Complete esponse Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, MD, MSc Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute Emory

More information

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited

More information

Anaplastic Thyroid Cancer:

Anaplastic Thyroid Cancer: 1 Anaplastic Thyroid Cancer: A Doctor s Perspective for Patients and Families Living with the Disease By Maria E. Cabanillas, M.D., F.A.C.E. Associate Professor and Faculty Director of Clinical Research

More information

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15 Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Foundational Issues Related to Immunotherapy and Melanoma

Foundational Issues Related to Immunotherapy and Melanoma Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

A Randomized Placebo Controlled Study of Erlotinib (OSI-774, Tarceva

A Randomized Placebo Controlled Study of Erlotinib (OSI-774, Tarceva A Randomized Placebo Controlled Study of Erlotinib (OSI-774, Tarceva ) ) versus Placebo in Patients with Incurable Non-Small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic

More information

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012 Overview of Ovarian Cancer Dr. Sinead Noonan 13/03/2012 Ovarian Cancer 4 th most common cause of cancer death in women 15,000 deaths/year in the US Each year 300 new cases in Ireland 80% epithelial cell

More information

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial S. Aebi, S. Gelber, I. Láng, S.J. Anderson, A. Robidoux, M. Martín, J.W.R. Nortier, E.P. Mamounas,

More information

Chirurgie des métastases cérébrales. Dr Mark Dexter Head, Department of Neurosurgery The Westmead Hospitals

Chirurgie des métastases cérébrales. Dr Mark Dexter Head, Department of Neurosurgery The Westmead Hospitals Chirurgie des métastases cérébrales Dr Mark Dexter Head, Department of Neurosurgery The Westmead Hospitals The Westmead patient population THE INCONVENIENT TRUTHS Cerebral metastases occur in 10 16 % of

More information

Timing of TKI s pre- or post-nephrectomy

Timing of TKI s pre- or post-nephrectomy Timing of TKI s pre- or post-nephrectomy Dr Simon Crabb Senior Lecturer and Honorary Consultant in Medical Oncology Cancer Sciences Unit, University of Southampton Faculty of Medicine Initial nephrectomy

More information

LUNG CANCER the new Staging System G.KIROVA TOKUDA HOSPITAL SOFIA

LUNG CANCER the new Staging System G.KIROVA TOKUDA HOSPITAL SOFIA LUNG CANCER the new Staging System G.KIROVA TOKUDA HOSPITAL SOFIA STAGING SYSTEM Provides standardized nomenclature for exchanging information Groups patients according to the biologic behavior of their

More information

Indications for Surgical Resection of Primary Lung Neoplasms Controversies, Problems and Techniques

Indications for Surgical Resection of Primary Lung Neoplasms Controversies, Problems and Techniques Indications for Surgical Resection of Primary Lung Neoplasms Controversies, Problems and Techniques Joshua Sonett, MD Weiskopf Professor of Surgical Oncology Chief Section of Thoracic Surgery Columbia

More information

Guidelines for the treatment of breast cancer with radiotherapy

Guidelines for the treatment of breast cancer with radiotherapy London Cancer Guidelines for the treatment of breast cancer with radiotherapy March 2013 Review March 2014 Version 1.0 Contents 1. Introduction... 3 2. Indications and dosing schedules... 3 2.1. Ductal

More information

See page 6 of this form for definitions / instructions to assist you in completing Question 1.

See page 6 of this form for definitions / instructions to assist you in completing Question 1. Pre-PET Form Comment to Clinician: You have requested an F-18 Fluoride PET scan, a test for which the Centers for Medicare and Medicaid Services (CMS) requires pre- and post-pet information from the referring

More information

Coxsackievirus A21 (CAVATAK TM ) - mediated oncolytic immunotherapy in advanced melanoma patients

Coxsackievirus A21 (CAVATAK TM ) - mediated oncolytic immunotherapy in advanced melanoma patients Coxsackievirus A21 (CAVATAK TM ) - mediated oncolytic immunotherapy in advanced melanoma patients Robert H.I. Andtbacka 1, Brendan Curti 2, Mark Grose 3, Len Post 4, Jeffrey Ira Weisberg 4 and Darren Shafren

More information

Lung Cancer: Diagnosis, Staging and Treatment

Lung Cancer: Diagnosis, Staging and Treatment PATIENT EDUCATION patienteducation.osumc.edu Lung Cancer: Diagnosis, Staging and Treatment Cancer starts in our cells. Cells are the building blocks of our tissues. Tissues make up the organs of the body.

More information

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer

More information

Immunotherapy Concept Turned Reality

Immunotherapy Concept Turned Reality Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a

More information

Management of Unresected Stage Ill Non-Small Cell Lung Cancer

Management of Unresected Stage Ill Non-Small Cell Lung Cancer Evidence-based Series 7-3 Version 2.2005 [TO BE UPDATED] A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Management of Unresected Stage Ill Non-Small Cell Lung

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

1 of 6 6/1/13 6:49 PM

1 of 6 6/1/13 6:49 PM A service of the U.S. National Institutes of Health Trial record 7 of 203 for: Melanoma Analysis Previous Study Return to List Next Study Expression Analysis of Specific Markers in Non-small Cell Lung

More information

The evolution of rectal cancer therapy. Objectives

The evolution of rectal cancer therapy. Objectives The evolution of rectal cancer therapy Hagen Kennecke MD MHA FRCPC Western Canada Consensus Conference September 5, 2014 Objectives Identify standard therapy: stage II/III rectal cancer Update recent adjuvant

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

Immune Therapy for Pancreatic Cancer

Immune Therapy for Pancreatic Cancer Immune Therapy for Pancreatic Cancer December 16, 2014 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only:

More information

Radiotherapy in Lung

Radiotherapy in Lung Radiotherapy in Lung CancerAnatomy Oblique fissure in both lungs. Horizontal fissure in Right lung. Trachea bifurcates at the level of T5. Lymph nodes are divided into stations. Intrapulmonary, bronchopulmonary

More information

Lung Cancer and Mesothelioma

Lung Cancer and Mesothelioma Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant

More information

Management of Non-Small Cell Lung Cancer Guide for General Practitioners

Management of Non-Small Cell Lung Cancer Guide for General Practitioners Management of n-small Cell Lung Cancer Guide for General Practitioners Clinical Stage I Cancer only in one lobe of lung and

More information

The Role of the Oncotype DX Breast Cancer Assay in the Neoadjuvant Setting

The Role of the Oncotype DX Breast Cancer Assay in the Neoadjuvant Setting 1 The Role of the Oncotype DX Breast Cancer Assay in the Neoadjuvant Setting 2 Neoadjuvant Therapy and Oncotype DX Case Study: Neoadjuvant Therapy Neoadjuvant Therapy in Breast Cancer Role of Oncotype

More information

Breast Cancer. Introduction

Breast Cancer. Introduction Breast Cancer Introduction Breast cancer is the commonest cancer in women in the UK and most patients are being diagnosed at an early stage due the success of the NHS Breast Screening Program. Radiotherapy

More information